Zostavax market forecast points to growth through 2035
The Business Research Company says the Zostavax vaccine market is set to expand as aging populations, higher shingles risk, and broader vaccine access lift demand. The report says North America led the market in 2025, with growth supported by healthcare infrastructure, insurance coverage, and preventive-care spending.
Why it matters: - Zostavax demand is tied to shingles prevention for older adults, a growing public-health need as populations age. - The market outlook suggests vaccine access, preventive care spending, and distribution infrastructure could shape adoption through 2035. - Zostavax is positioned as a preventive tool for adults 50 and older to reduce shingles and postherpetic neuralgia.
What happened: - The Business Research Company released a Zostavax market report covering market size, trends, and global forecasts for 2026-2035. - The report says North America held the largest share of the global Zostavax market in 2025. - The outlook also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The company also made a free sample of the report available here. - The full report is available here.
The details: - Zostavax protects adults, especially those 50 and older, from shingles caused by reactivation of the varicella-zoster virus. - The vaccine is intended to lower the risk of complications, including lasting nerve pain from postherpetic neuralgia. - Historical growth has been driven by older demographics, higher shingles rates among seniors, immunization guidelines, live attenuated vaccine availability, and wider vaccination in hospitals. - Future growth is expected to benefit from a shift toward newer recombinant vaccines, higher healthcare spending on prevention, greater awareness of postherpetic neuralgia, broader adult vaccination programs, and better vaccine distribution systems. - Key trends include expanded adult immunization campaigns, more shingles awareness, easier access through retail pharmacies, stronger cold chain management, and a broader focus on preventive healthcare. - Healthcare infrastructure expansion in developing nations is helping make vaccine delivery easier across hospitals, clinics, and pharmacies. - The UK Department of Health and Social Care said in May 2023 that the government allocated more than $25.33 billion (£20 billion) for the New Hospital Programme to build 40 new hospitals in England by 2030, including mental health facilities. - The aging population is adding to the addressable market for shingles vaccination. - In July 2024, the UK Parliament's House of Commons Library said the UK had 12.7 million residents aged 65 or older in 2022, equal to 19% of the population, with that share projected to reach 27% by 2072. - Broader insurance coverage is also supporting vaccine uptake by lowering the cost barrier for adults. - Health Affairs reported in June 2024 that about 92.3% of the U.S. population, or about 316 million people, had health coverage, while 7.7%, or 26 million people, remained uninsured.
Between the lines: - The report points to a market shaped less by the vaccine alone and more by the systems around it: aging demographics, coverage, healthcare infrastructure, and pharmacy distribution. - The mention of newer recombinant vaccines suggests Zostavax faces competition from newer prevention options even as the broader shingles market grows. - Expanded strategic intelligence in the 2026 report edition signals a stronger emphasis on investor and planning use cases, not just demand estimates.
What's next: - The market will likely track the pace of adult immunization campaigns, insurance coverage, and healthcare infrastructure investment. - Adoption will also depend on how quickly vaccine delivery improves in hospitals, retail pharmacies, and other care settings. - The report says its updated 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis. - The Business Research Company lists Saumya Sahay as a contact for more information.
The bottom line: - Zostavax remains a niche but relevant part of the shingles-prevention market, with growth tied to aging populations and better access to preventive care.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Euro Broadcast News
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.